|
Post by JHam on Feb 17, 2021 16:28:51 GMT
Just took a small chunk off the table. I started getting antsy watching this thing drop a bit. Not panicking, but the 2021 JHam has sworn an oath to himself to always secure some profits
|
|
|
Post by JHam on Feb 18, 2021 15:17:20 GMT
I went ahead and dumped the rest of my position here today at $10.50. It could certainly jump on FDA approval news, and I am keeping it on my watchlist. But the moron pump happening right now has killed the potential rally imo, and a 70% total realized gain in a couple of weeks did the trick. Good luck to everyone continuing to hold.
|
|
|
Post by magnus123 on Feb 18, 2021 15:39:06 GMT
I went ahead and dumped the rest of my position here today at $10.50. It could certainly jump on FDA approval news, and I am keeping it on my watchlist. But the moron pump happening right now has killed the potential rally imo, and a 70% total realized gain in a couple of weeks did the trick. Good luck to everyone continuing to hold. Congrats! I will follow you in the next days and sold the first portion today. Too much stupid money in KMPH. Bought instead a little bit more INMB and OPTN.
|
|
|
Post by JHam on Feb 18, 2021 15:41:06 GMT
I went ahead and dumped the rest of my position here today at $10.50. It could certainly jump on FDA approval news, and I am keeping it on my watchlist. But the moron pump happening right now has killed the potential rally imo, and a 70% total realized gain in a couple of weeks did the trick. Good luck to everyone continuing to hold. Congrats! I will follow you in the next days and sold the first portion today. Too much stupid money in KMPH. Bought instead a little bit more INMB and OPTN. Congrats to you too! *See my post from 15 seconds ago in the OPTN thread.
|
|
|
Post by magnus123 on Feb 18, 2021 21:49:10 GMT
Nice bids in KMPH out of the blue. Can't find any news. No shares available to borrow at IB. Massively shorted today. While i'm still skeptical, i see the opportunity in the next week...
|
|
|
Post by JHam on Feb 19, 2021 0:58:41 GMT
Nice bids in KMPH out of the blue. Can't find any news. No shares available to borrow at IB. Massively shorted today. While i'm still skeptical, i see the opportunity in the next week... Now that I’ve secured profits, if it dips down again I may re-buy.
|
|
|
Post by magnus123 on Feb 22, 2021 22:28:48 GMT
|
|
|
Post by JHam on Feb 22, 2021 23:29:04 GMT
Interesting. I wonder what that’s about.
|
|
|
Post by magnus123 on Feb 23, 2021 10:00:25 GMT
Interesting. I wonder what that’s about. Maybe just a general presentation.
|
|
|
Post by magnus123 on Feb 24, 2021 21:08:54 GMT
*UPDATE* KMPH has decided to postpone this event until AFTER the PDUFA date. Please disregard the 4/14 date. This will be updated as soon as we have a new date and time.
|
|
|
Post by JHam on Feb 25, 2021 15:12:57 GMT
Glad I followed my gut here (sheer luck) and got out when I did. Down to $8.82 as I write this. I don’t think anything has changed fundamentally or with the upcoming PDUFA date/FDA decision. But the over-the-top manufactured pump fizzled out the run-up that was already occurring naturally. If it dips below $8 in the next few days I might jump back in with a small position.
|
|
|
Post by magnus123 on Feb 25, 2021 15:23:40 GMT
Glad I followed my gut here (sheer luck) and got out when I did. Down to $8.82 as I write this. I don’t think anything has changed fundamentally or with the upcoming PDUFA date/FDA decision. But the over-the-top manufactured pump fizzled out the run-up that was already occurring naturally. If it dips below $8 in the next few days I might jump back in with a small position. I'm currently buying $10 calls. I still expect a fomo move before PDUFA and I will sell my entire share position in that case, holding only my calls. Much lower exposure for me with big upside potential.
|
|
|
Post by JHam on Feb 25, 2021 15:30:38 GMT
Glad I followed my gut here (sheer luck) and got out when I did. Down to $8.82 as I write this. I don’t think anything has changed fundamentally or with the upcoming PDUFA date/FDA decision. But the over-the-top manufactured pump fizzled out the run-up that was already occurring naturally. If it dips below $8 in the next few days I might jump back in with a small position. I'm currently buying $10 calls. I still expect a fomo move before PDUFA and I will sell my entire share position in that case, holding only my calls. Much lower exposure for me with big upside potential. Great idea!
|
|
|
Post by JHam on Feb 25, 2021 16:23:52 GMT
The current ask on those $10 March calls is $1.95, lol.
|
|
|
Post by magnus123 on Feb 25, 2021 18:01:10 GMT
I exchanged now most of my share position against a full call position. I feel much better now with a lot of cash on hand. Also sold stocks that i bought on tuesday, where i was still green. I don't like this market... I'm more than 25% in cash.
|
|
|
Post by JHam on Feb 25, 2021 18:23:13 GMT
I exchanged now most of my share position against a full call position. I feel much better now with a lot of cash on hand. Also sold stocks that i bought on tuesday, where i was still green. I don't like this market... I'm more than 25% in cash. Nice job. Yeah I am currently 30% in cash which is actually a little less than I feel comfortable with. I couldn’t resist EQ dipping so low. Contemplated taking advantage of TAIT being back at $4.50, but couldn’t pull the trigger. It will likely be back over $5 as soon as this settles down.
|
|
|
Post by magnus123 on Feb 25, 2021 19:01:54 GMT
I exchanged now most of my share position against a full call position. I feel much better now with a lot of cash on hand. Also sold stocks that i bought on tuesday, where i was still green. I don't like this market... I'm more than 25% in cash. Nice job. Yeah I am currently 30% in cash which is actually a little less than I feel comfortable with. I couldn’t resist EQ dipping so low. Contemplated taking advantage of TAIT being back at $4.50, but couldn’t pull the trigger. It will likely be back over $5 as soon as this settles down. 30% is solid with a stable QUIK and OPTN. I just had to avoid the liquidity trap today...
|
|
|
Post by magnus123 on Mar 1, 2021 9:21:00 GMT
More than 30% up right now. Could be a nice day!
|
|
|
Post by JHam on Mar 1, 2021 12:08:09 GMT
More than 30% up right now. Could be a nice day! ATNX had their PDUFA decision today and received a CRL from the FDA. Ouch. This is why I am scared to hold through PDUFA. Many on the KMPH ST board were saying how they were going to take profits from ATNX and roll it into KMPH before tomorrow. I guess that plan is shot: www.stocktitan.net/news/ATNX/athenex-receives-fda-complete-response-letter-for-oral-paclitaxel-1nwa93xks2e8.htmlAthenex Receives FDA Complete Response Letter for Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer share: Share on Facebook Tweet on Twitter Post to Reddit
March 1, 2021 - 7:00 am Conference call and webcast scheduled for today at 8:00 a.m. ET BUFFALO, N.Y., March 01, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the company's New Drug Application (NDA) for oral paclitaxel plus encequidar for the treatment of metastatic breast cancer. The FDA issues a CRL to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form.
In the CRL, the FDA indicated its concern of safety risk to patients in terms of an increase in neutropenia-related sequelae on the Oral Paclitaxel arm compared with the IV paclitaxel arm.
The FDA also expressed concerns regarding the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by blinded independent central review (BICR). The Agency stated that the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR.
The agency recommended that Athenex conduct a new adequate and well-conducted clinical trial in a patient population with metastatic breast cancer representative of the population in the U.S. The Agency determined that additional risk mitigation strategies to improve toxicity, which may involve dose optimization and / or exclusion of patients deemed to be at higher risk of toxicity, are required to support potential approval of the NDA.
Athenex plans to request a meeting with the FDA to discuss the Agency's response, engage in a dialogue on the design and scope of a clinical trial to address the FDA's requirements and align on the next steps required to obtain approval.
"Our clinical and regulatory teams are disappointed by the complete response letter," said Dr. Rudolf Kwan, Chief Medical Officer of Athenex. "We plan to work with the Agency to resolve the issues raised in the CRL and to obtain approval for oral paclitaxel plus encequidar in metastatic breast cancer."
Dr. Johnson Lau, Chief Executive Officer of Athenex, added, "We remain committed to the breast cancer community and will explore the best path forward to obtain regulatory approval. In the interim, we will identify and undertake the appropriate internal organizational adjustments accordingly."
|
|
|
Post by JHam on Mar 1, 2021 12:36:38 GMT
Halt just lifted on ATNX. Getting absolutely crushed.
|
|